|
graph representation learning |
4 |
|
b-spline |
3 |
|
causal inference |
3 |
|
censored quantile regression |
3 |
|
covid-19 |
3 |
|
e-learning |
3 |
|
electronic health records |
3 |
|
face-to-face learning |
3 |
|
functional regression |
3 |
|
generalized approximate cross-validation |
3 |
|
multi-task learning |
3 |
|
online teaching |
3 |
|
randomized controlled experiment |
3 |
|
teaching effectiveness |
3 |
|
time-varying effect |
3 |
|
bayes factor |
2 |
|
bayesian design |
2 |
|
bayesian inference |
2 |
|
bayesian model selection |
2 |
|
bayesian networks |
2 |
|
biased coin design |
2 |
|
box-cox transformation |
2 |
|
clinical trial |
2 |
|
convergence |
2 |
|
covariate balance |
2 |
|
covariate-adaptive randomization |
2 |
|
cure fraction |
2 |
|
deep learning |
2 |
|
dividend management |
2 |
|
drug repurposing |
2 |
|
exact line search |
2 |
|
gibbs sampling |
2 |
|
greedy algorithm |
2 |
|
hessian sketch |
2 |
|
investment |
2 |
|
late-onset toxicity |
2 |
|
magnetic resonance imaging |
2 |
|
markov chain approximation |
2 |
|
mixture cure model |
2 |
|
network biology |
2 |
|
network pharmacology |
2 |
|
neural network |
2 |
|
odds ratio |
2 |
|
optimal design |
2 |
|
parallel processing systems |
2 |
|
phase i trial |
2 |
|
pocock and simon design |
2 |
|
preconditioner |
2 |
|
reinsurance |
2 |
|
stochastic approximation |
2 |
|
subsampling |
2 |
|
3 + 3 design |
1 |
|
absolute risk reduction |
1 |
|
accelerated failure time model |
1 |
|
adaptive design |
1 |
|
adaptive lasso |
1 |
|
adaptive randomization |
1 |
|
additive hazards |
1 |
|
additive hazards model |
1 |
|
additive model |
1 |
|
adolescent |
1 |
|
adult |
1 |
|
adversarial learning |
1 |
|
affymetrix |
1 |
|
aged |
1 |
|
aged, 80 and over |
1 |
|
algorithms |
1 |
|
analysis of variance |
1 |
|
animals |
1 |
|
anthracyclines - therapeutic use |
1 |
|
antibodies, monoclonal - therapeutic use |
1 |
|
antibodies, monoclonal, humanized |
1 |
|
antibodies, monoclonal, murine-derived - therapeutic use |
1 |
|
antineoplastic agents - administration & dosage |
1 |
|
antineoplastic agents - therapeutic use |
1 |
|
antineoplastic combined chemotherapy protocols - administration & dosage |
1 |
|
antineoplastic combined chemotherapy protocols - adverse effects - therapeutic use |
1 |
|
antineoplastic combined chemotherapy protocols - pharmacology |
1 |
|
asymptomatic case |
1 |
|
asymptotic distribution |
1 |
|
asymptotic normality |
1 |
|
asymptotic optimality |
1 |
|
attention |
1 |
|
augmented equation |
1 |
|
averaging estimation |
1 |
|
bagging |
1 |
|
basic helix-loop-helix transcription factors - genetics - metabolism |
1 |
|
basket trial |
1 |
|
bayes theorem |
1 |
|
bayesian adaptive design |
1 |
|
bayesian computation |
1 |
|
bayesian error rates |
1 |
|
bayesian estimation |
1 |
|
bayesian model averaging |
1 |
|
bayesian non-parametrics |
1 |
|
bayesian posterior probability |
1 |
|
bayesian statistical decision theory. |
1 |
|
bayesian trial design |
1 |
|
bet design |
1 |
|
bias (epidemiology) |
1 |
|
bic |
1 |
|
binary endpoint |
1 |
|
biomarker |
1 |
|
biomarker cutoff |
1 |
|
biomarker design |
1 |
|
biomarker study |
1 |
|
biometry |
1 |
|
biometry - methods |
1 |
|
biopsy, fine-needle |
1 |
|
biopsy, needle - adverse effects - methods |
1 |
|
bivariate binary model |
1 |
|
bivariate survival function |
1 |
|
blocked gibbs sampler |
1 |
|
body fluids - cytology |
1 |
|
boosting |
1 |
|
bootstrap |
1 |
|
bootstrap sample |
1 |
|
bradley–terry model |
1 |
|
brain neoplasms - drug therapy - secondary |
1 |
|
brain neoplasms - metabolism - pathology - secondary |
1 |
|
breast |
1 |
|
breast - metabolism - pathology |
1 |
|
breast - pathology |
1 |
|
breast cancer |
1 |
|
breast carcinoma |
1 |
|
breast neoplasms |
1 |
|
breast neoplasms - blood supply - enzymology - metabolism - pathology |
1 |
|
breast neoplasms - diagnosis - pathology - prevention & control |
1 |
|
breast neoplasms - drug therapy - enzymology |
1 |
|
breast neoplasms - drug therapy - enzymology - pathology |
1 |
|
breast neoplasms - drug therapy - mortality |
1 |
|
breast neoplasms - drug therapy - pathology |
1 |
|
breast neoplasms - drug therapy - secondary |
1 |
|
breast neoplasms - genetics - pathology |
1 |
|
breast neoplasms - mortality - pathology - therapy |
1 |
|
bridged compounds - therapeutic use |
1 |
|
b‐spline |
1 |
|
cancer |
1 |
|
cancer survivor |
1 |
|
cancer treatment |
1 |
|
cancer vaccines - therapeutic use |
1 |
|
capecitabine |
1 |
|
carbazoles - pharmacology |
1 |
|
carcinoma, intraductal, noninfiltrating - drug therapy - pathology |
1 |
|
carcinoma, non-small-cell lung - genetics |
1 |
|
carcinoma, non-small-cell lung - metabolism - pathology - secondary |
1 |
|
categorical data |
1 |
|
cell line, tumor |
1 |
|
censored data |
1 |
|
censoreddata |
1 |
|
censoring |
1 |
|
central limit theorem |
1 |
|
change points |
1 |
|
change-point detection |
1 |
|
change-point estimation |
1 |
|
check function |
1 |
|
chemotherapy |
1 |
|
chemotherapy, adjuvant |
1 |
|
child |
1 |
|
child, preschool |
1 |
|
chromosomal instability |
1 |
|
chromosome aberrations |
1 |
|
chromosomes, human, pair 1 - genetics |
1 |
|
chromosomes, human, pair 11 - genetics |
1 |
|
chromosomes, human, pair 17 - genetics |
1 |
|
chromosomes, human, pair 8 - genetics |
1 |
|
clinical trial ethics |
1 |
|
clinical trials |
1 |
|
clinical trials -- statistical methods. |
1 |
|
clinical trials as topic |
1 |
|
clinical trials as topic - methods |
1 |
|
clinical trials as topic - statistics & numerical data |
1 |
|
clinical trials as topic -- methods |
1 |
|
clinical trials, phase i as topic |
1 |
|
clinical trials, phase i as topic - statistics & numerical data |
1 |
|
clinical trials, phase ii as topic - statistics & numerical data |
1 |
|
close contact |
1 |
|
cluster analysis |
1 |
|
cohort studies |
1 |
|
combined drugs |
1 |
|
combined modality |
1 |
|
combined modality therapy |
1 |
|
combining drugs |
1 |
|
computer simulation |
1 |
|
computer simulation - statistics & numerical data |
1 |
|
concave penalization |
1 |
|
concordance index |
1 |
|
conditional logit model |
1 |
|
conditional power |
1 |
|
confidence band |
1 |
|
confidence interval |
1 |
|
confidence intervals |
1 |
|
constrained optimization |
1 |
|
constrained parameter |
1 |
|
contingency table |
1 |
|
continual reassessment method |
1 |
|
controlled clinical trials as topic - statistics & numerical data |
1 |
|
convex optimizations |
1 |
|
copula model |
1 |
|
coronary artery disease |
1 |
|
coronavirus |
1 |
|
corrected estimating equation |
1 |
|
correlated data |
1 |
|
correlated failure time |
1 |
|
correlated failure time data |
1 |
|
correlated survival data |
1 |
|
correlation |
1 |
|
count data |
1 |
|
counting process |
1 |
|
covariate adjustment |
1 |
|
covid-19 diagnosis |
1 |
|
cpo |
1 |
|
cramér–von mises statistic |
1 |
|
cross validation |
1 |
|
ct image |
1 |
|
cumulative residual |
1 |
|
cumulative sum |
1 |
|
cure model |
1 |
|
cure rate model |
1 |
|
cure threshold model |
1 |
|
curvature regularization |
1 |
|
cytodiagnosis - methods |
1 |
|
cytostatic agent |
1 |
|
dacarbazine - administration & dosage - adverse effects - analogs & derivatives |
1 |
|
data analysis |
1 |
|
data interpretation, statistical |
1 |
|
deep neural network |
1 |
|
delaunay triangle |
1 |
|
delayed response |
1 |
|
density estimation |
1 |
|
dental pulp diseases - epidemiology |
1 |
|
dentistry - statistics & numerical data |
1 |
|
deoxycytidine - administration & dosage - adverse effects - analogs & derivatives |
1 |
|
detectable treatment difference |
1 |
|
deviance information criterion |
1 |
|
diabetes complications - mortality |
1 |
|
diabetes mellitus - drug therapy - mortality |
1 |
|
diagnosis |
1 |
|
dic |
1 |
|
dimension reduction |
1 |
|
discharge |
1 |
|
discrete choice |
1 |
|
discrete markov gamma process |
1 |
|
disease progression |
1 |
|
disease-free survival |
1 |
|
distribution alignment |
1 |
|
dmf index |
1 |
|
dna methylation |
1 |
|
dobrushin condition |
1 |
|
docetaxel |
1 |
|
dose de-escalation |
1 |
|
dose escalation |
1 |
|
dose finding |
1 |
|
dose intensity |
1 |
|
dose-finding study |
1 |
|
dose-finding trial |
1 |
|
dose-response curve |
1 |
|
dose-response relationship, drug |
1 |
|
down-regulation |
1 |
|
doxorubicin - administration & dosage |
1 |
|
drug administration schedule |
1 |
|
drug combination |
1 |
|
drug combinations |
1 |
|
drug efficacy |
1 |
|
drug safety |
1 |
|
drug therapy, combination |
1 |
|
drug therapy, computer-assisted - methods |
1 |
|
drug toxicity |
1 |
|
ductal carcinoma in situ |
1 |
|
dynamic asset allocation |
1 |
|
dynamic ordering |
1 |
|
dynamic prediction |
1 |
|
dynamic programming |
1 |
|
early termination |
1 |
|
early treatment effect |
1 |
|
effective dose |
1 |
|
efficacy |
1 |
|
efficient estimator |
1 |
|
empirical distribution function |
1 |
|
empirical estimation |
1 |
|
empirical likelihood |
1 |
|
empirical process |
1 |
|
enrichment strategies |
1 |
|
ensemble learning |
1 |
|
enzyme activation - drug effects - physiology |
1 |
|
epidemiology |
1 |
|
equilibrium control |
1 |
|
equivalence contour |
1 |
|
erbb2 |
1 |
|
errors-in-variables problem |
1 |
|
estimating equation |
1 |
|
estimating equations |
1 |
|
estimation efficiency |
1 |
|
expectation-maximization algorithm |
1 |
|
expected sample size |
1 |
|
exponential distribution |
1 |
|
failure time data |
1 |
|
fatigue - chemically induced |
1 |
|
feature screening |
1 |
|
female |
1 |
|
fisher exact test |
1 |
|
fluorouracil - analogs & derivatives |
1 |
|
follow up |
1 |
|
follow-up studies |
1 |
|
frailty model |
1 |
|
frequentist hypothesis testing |
1 |
|
futility termination |
1 |
|
g-csf |
1 |
|
gaussian quadrature |
1 |
|
gcn |
1 |
|
gene dosage - genetics - physiology |
1 |
|
gene expression |
1 |
|
generalized estimating equation |
1 |
|
generalized linear model |
1 |
|
generalized method of moments |
1 |
|
generalized partially linear model |
1 |
|
gibbs sampler |
1 |
|
glutathione s-transferase pi - metabolism |
1 |
|
goodness-of-fit test |
1 |
|
graft survival |
1 |
|
graph neural network |
1 |
|
group lasso |
1 |
|
group sequential method |
1 |
|
group sequential methods |
1 |
|
hazard function |
1 |
|
heart failure |
1 |
|
heterogeneity |
1 |
|
heterogeneous information network |
1 |
|
hierarchical model |
1 |
|
high-dimensional covariance matrix |
1 |
|
high-dimensional homogeneity test |
1 |
|
high-risk women |
1 |
|
highest posterior density interval |
1 |
|
homogeneity test |
1 |
|
human |
1 |
|
humans |
1 |
|
hyperplasia |
1 |
|
hypothesis testing |
1 |
|
identifiability |
1 |
|
immunohistochemistry |
1 |
|
in situ hybridization, fluorescence - methods |
1 |
|
incomplete multinomial model |
1 |
|
indoles - pharmacology |
1 |
|
infant |
1 |
|
information storage and retrieval - methods |
1 |
|
informative missing data |
1 |
|
interferon-alpha - therapeutic use |
1 |
|
interim analysis |
1 |
|
interpretation of p-value |
1 |
|
interval censoring |
1 |
|
interval design |
1 |
|
invasion |
1 |
|
isolated recurrence |
1 |
|
iterative monte carlo |
1 |
|
kaplan-meier estimate |
1 |
|
kaplan-meier estimator |
1 |
|
kernel function |
1 |
|
kernel smoothing |
1 |
|
landmark analysis |
1 |
|
late-onset toxicityphase i clinical trial |
1 |
|
latent variable |
1 |
|
least-squares refitting |
1 |
|
lesion localization |
1 |
|
letter |
1 |
|
ligands |
1 |
|
likelihood functions |
1 |
|
likelihood ratio test |
1 |
|
linear transformation model |
1 |
|
linear transformation models |
1 |
|
local polynomial |
1 |
|
locally advanced |
1 |
|
log rank test |
1 |
|
log-rank test |
1 |
|
logistic models |
1 |
|
long term survival |
1 |
|
long-term survivor |
1 |
|
loss function |
1 |
|
lung cancer |
1 |
|
lung neoplasms - genetics |
1 |
|
lung neoplasms - metabolism - pathology - secondary |
1 |
|
lutathione-s-transferase-pi |
1 |
|
machine learning |
1 |
|
male |
1 |
|
marginal model |
1 |
|
markov chain monte carlo |
1 |
|
markov chain monte carlo simulation |
1 |
|
markov chains |
1 |
|
markov gamma process |
1 |
|
martingale |
1 |
|
martingale residual |
1 |
|
masking |
1 |
|
maximum likelihood |
1 |
|
maximum likelihood estimator |
1 |
|
maximum tolerated dose |
1 |
|
maximum tolerated dose contour |
1 |
|
mean–variance portfolio selection |
1 |
|
measurement error |
1 |
|
mechanical ventilation |
1 |
|
median regression |
1 |
|
medical oncology - methods |
1 |
|
medical risk factors |
1 |
|
melanoma - mortality - therapy |
1 |
|
metastasis |
1 |
|
metastatic breast cancer |
1 |
|
methylation |
1 |
|
metropolis algorithm |
1 |
|
metropolis-hastings algorithm |
1 |
|
mice |
1 |
|
mice, scid |
1 |
|
microarray |
1 |
|
middle aged |
1 |
|
minimum covariance determinant estimator |
1 |
|
missing data |
1 |
|
mitogen-activated protein kinase kinases - metabolism |
1 |
|
mixture prior |
1 |
|
model assumption |
1 |
|
model averaging |
1 |
|
model diagnostic |
1 |
|
model diagnostics |
1 |
|
model selection |
1 |
|
model-based |
1 |
|
model-free |
1 |
|
model-free screening |
1 |
|
models, biological |
1 |
|
models, statistical |
1 |
|
moment calibration |
1 |
|
moment condition |
1 |
|
monte carlo method |
1 |
|
mortality |
1 |
|
msc 2010: primary 62n01 |
1 |
|
multi-sample comparison |
1 |
|
multiple change-point detection |
1 |
|
multiple change-points |
1 |
|
multiple imputation |
1 |
|
multiple robustness |
1 |
|
multiple testing |
1 |
|
multivariate analysis |
1 |
|
multivariate data |
1 |
|
multivariate failure time data |
1 |
|
multivariate failure times |
1 |
|
multivariate survival analysis |
1 |
|
myringoplasty |
1 |
|
nausea - chemically induced |
1 |
|
neoadjuvant systemic therapy |
1 |
|
neoadjuvant therapy |
1 |
|
neoplasm invasiveness - pathology - prevention & control |
1 |
|
neoplasm metastasis |
1 |
|
neoplasm metastasis - drug therapy - prevention & control |
1 |
|
neoplasm recurrence, local - therapy |
1 |
|
neoplasm staging |
1 |
|
neoplasms, hormone-dependent - drug therapy - enzymology |
1 |
|
neovascularization, pathologic - metabolism - pathology |
1 |
|
network meta-analysis |
1 |
|
neural metastases |
1 |
|
nih 3t3 cells |
1 |
|
non proportional hazards |
1 |
|
nonignorable dropout |
1 |
|
nonignorable missing data |
1 |
|
nonlocal prior |
1 |
|
nonmaximum suppression |
1 |
|
nonparametric estimation |
1 |
|
nonparametric estimator |
1 |
|
nonparametric maximum likelihood estimation |
1 |
|
nonparametric method |
1 |
|
nonparametric regression |
1 |
|
non‐parametric design |
1 |
|
normal distribution |
1 |
|
northwestern united states - epidemiology |
1 |
|
npmle |
1 |
|
number needed to treat |
1 |
|
oncology trials |
1 |
|
one-sided test |
1 |
|
optimal biological dose |
1 |
|
oracle property |
1 |
|
ordinal data |
1 |
|
otitis media - surgery |
1 |
|
outcome assessment (health care) - methods |
1 |
|
overall survival |
1 |
|
overdose control |
1 |
|
p-value |
1 |
|
pair chart statistic |
1 |
|
parallel hazards |
1 |
|
parametric model |
1 |
|
patient heterogeneity |
1 |
|
pearson statistic |
1 |
|
penalized function |
1 |
|
penalty |
1 |
|
peptide |
1 |
|
perturbation |
1 |
|
perturbation resampling |
1 |
|
pharmaceutical preparations - administration & dosage |
1 |
|
phase 3 clinical trial (topic) |
1 |
|
phase i clinical trial |
1 |
|
phase i/ii trial |
1 |
|
phase ii clinical trial |
1 |
|
phase ii trial |
1 |
|
phase iii clinical trial |
1 |
|
phase iii trial designs |
1 |
|
phosphatidylinositol 3-kinases - metabolism |
1 |
|
phosphorylation |
1 |
|
piecewise exponential distributio |
1 |
|
piecewise linear |
1 |
|
pkcα |
1 |
|
platelets |
1 |
|
point cloud data |
1 |
|
point mutation - genetics |
1 |
|
point null hypothesis |
1 |
|
poisson-dirichlet process |
1 |
|
posterior distribution |
1 |
|
posterior error rate |
1 |
|
posterior model probability |
1 |
|
posterior predictive distribution |
1 |
|
posterior probability |
1 |
|
posterior sample |
1 |
|
power |
1 |
|
power calculation |
1 |
|
power enhancement |
1 |
|
prediction |
1 |
|
predictive marker |
1 |
|
prior distributions |
1 |
|
probability |
1 |
|
probit model |
1 |
|
prognosis |
1 |
|
prognosis and response predictions |
1 |
|
progression-free survival |
1 |
|
promoter regions, genetic |
1 |
|
promotion time cure model |
1 |
|
proof of concept |
1 |
|
proportional hazards |
1 |
|
proportional hazards cure model |
1 |
|
proportional hazards model |
1 |
|
proportional hazards models |
1 |
|
proportional hazards regression |
1 |
|
proportional odds model |
1 |
|
protein kinase c-alpha - antagonists & inhibitors - biosynthesis - metabolism |
1 |
|
protein kinase inhibitors - pharmacology |
1 |
|
protein kinases - metabolism |
1 |
|
proto-oncogene proteins c-akt - metabolism |
1 |
|
proto-oncogene proteins pp60(c-src) - antagonists & inhibitors - physiology |
1 |
|
pseudo maximum likelihood |
1 |
|
pseudo-empirical likelihood |
1 |
|
pyrimidines - pharmacology |
1 |
|
quantile estimation |
1 |
|
quantile regression |
1 |
|
radical prostatectomy |
1 |
|
random censoring |
1 |
|
random effects |
1 |
|
random scan |
1 |
|
randomization |
1 |
|
randomized controlled trials |
1 |
|
randomized controlled trials as topic |
1 |
|
randomized controlled trials as topic - methods |
1 |
|
randomized study |
1 |
|
randomized trial |
1 |
|
rank estimation |
1 |
|
receptor, epidermal growth factor - metabolism |
1 |
|
receptor, erbb-2 |
1 |
|
receptor, erbb-2 - metabolism |
1 |
|
receptor, erbb-2 - physiology |
1 |
|
receptor, erbb-3 - metabolism |
1 |
|
receptors, cell surface - antagonists & inhibitors - biosynthesis |
1 |
|
receptors, estrogen - analysis |
1 |
|
receptors, urokinase plasminogen activator |
1 |
|
recombinant proteins |
1 |
|
recommendation system |
1 |
|
recursive formula |
1 |
|
redistribution to the right |
1 |
|
regression analysis |
1 |
|
regression quantile |
1 |
|
regression quantiles |
1 |
|
repeated measures |
1 |
|
reporting |
1 |
|
research design |
1 |
|
residual lifetime |
1 |
|
response |
1 |
|
response-adaptive randomization |
1 |
|
restricted mean survival time |
1 |
|
retrospective studies |
1 |
|
reversible jump markov chain monte carlo |
1 |
|
reweighting |
1 |
|
ribosomal protein s6 kinases, 70-kda - metabolism |
1 |
|
risk assessment - methods |
1 |
|
risk factors |
1 |
|
rmst |
1 |
|
robust |
1 |
|
robustness |
1 |
|
root canal therapy |
1 |
|
root canal therapy - methods |
1 |
|
sample size |
1 |
|
sample size adjustment |
1 |
|
sample size re-estimation |
1 |
|
score process |
1 |
|
screening |
1 |
|
secondary 62n02 |
1 |
|
self-designing trial |
1 |
|
semiparametric |
1 |
|
semiparametric efficiency |
1 |
|
semiparametric efficiency bound |
1 |
|
semiparametric estimation |
1 |
|
semiparametric method |
1 |
|
semiparametric model |
1 |
|
semiparametric models |
1 |
|
semiparametric spline smoothing |
1 |
|
sensitivity and specificity |
1 |
|
shared-parameter model |
1 |
|
sieve estimation |
1 |
|
sieve maximum likelihood estimator |
1 |
|
simon's design |
1 |
|
single-index model |
1 |
|
single-to-double arm design |
1 |
|
single‐to‐double arm design |
1 |
|
smoothing spline |
1 |
|
sparse contingency table |
1 |
|
src |
1 |
|
stage iv-ned |
1 |
|
statistical inference |
1 |
|
statistics as topic |
1 |
|
statistics as topic - methods |
1 |
|
statistics as topic -- methods |
1 |
|
statistics, nonparametric |
1 |
|
stieltjes transform |
1 |
|
stochastic moves |
1 |
|
stopping rule |
1 |
|
subgroup analysis |
1 |
|
sure independent screening |
1 |
|
sure screening property |
1 |
|
surrogate |
1 |
|
survival |
1 |
|
survival analysis |
1 |
|
survival comparison |
1 |
|
survival curve |
1 |
|
survival data |
1 |
|
survival difference |
1 |
|
survival endpoint |
1 |
|
survival fraction |
1 |
|
survival function |
1 |
|
survival rate |
1 |
|
susceptibility |
1 |
|
swamping |
1 |
|
synergy |
1 |
|
targeted therapy design |
1 |
|
taxoids - administration & dosage |
1 |
|
taxoids - therapeutic use |
1 |
|
tcf21 |
1 |
|
temozolomide |
1 |
|
terminal event |
1 |
|
therapeutic irrigation |
1 |
|
time factors |
1 |
|
time inconsistency |
1 |
|
time to event |
1 |
|
time-to-event data |
1 |
|
time-to-event endpoint |
1 |
|
tooth extraction |
1 |
|
tooth loss |
1 |
|
tooth loss - epidemiology |
1 |
|
tooth, nonvital - epidemiology |
1 |
|
tor serine-threonine kinases |
1 |
|
toxicity |
1 |
|
toxicity contour |
1 |
|
toxicity probability |
1 |
|
toxicology - statistics & numerical data |
1 |
|
trade-offs |
1 |
|
transformation model |
1 |
|
transformed hazard rate |
1 |
|
transplantation, heterologous |
1 |
|
trastuzumab (herceptin) |
1 |
|
treatment effect |
1 |
|
treatment failure |
1 |
|
treatment outcome |
1 |
|
triangular mesh compression |
1 |
|
tumor markers, biological - genetics |
1 |
|
two-sided test |
1 |
|
two-stage design |
1 |
|
two-stage procedure |
1 |
|
two‐sample test |
1 |
|
two‐stage estimation |
1 |
|
type i error |
1 |
|
type i error rate |
1 |
|
type ii error |
1 |
|
ultrahigh dimensionality |
1 |
|
ultrahigh-dimensional data |
1 |
|
uniformly most powerful bayesian test |
1 |
|
up-and-down design. |
1 |
|
up-regulation |
1 |
|
up-regulation - drug effects |
1 |
|
utility function |
1 |
|
variable selection |
1 |
|
varying coefficient |
1 |
|
varying-coefficient model |
1 |
|
vascular endothelial growth factor a - biosynthesis |
1 |
|
volterra integral equation |
1 |
|
vomiting - chemically induced |
1 |
|
wasserstein metric |
1 |
|
wavelet approximation |
1 |
|
weighted average |
1 |
|
weighted score function |
1 |
|
weighted tests |
1 |
|
within-cluster resampling |
1 |
|
zero-inflated count data |
1 |
